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Background: Accumulating studies have focused on the oncogenic and tumor suppressive roles of the newly
identified lncRNAs. A novel lncRNA BC040587 in 3q13.31 locus which exists frequent copy number alterations was
found to be associated with poor survival of osteosarcoma patients. However, its role in breast cancer (BC) remains
unknown. The aim of this study was to examine the expression pattern of BC040587 in BC and to evaluate its
biological role and clinical significance in prediction of prognosis.
Methods: Expression of BC040587 was analyzed in 20 pairs of BC cancer tissues and adjacent noncancerous tissues
(ANCT), also in 151 BC tissues, 9 BC cell lines and one normal breast cell line by quantitative reverse-transcription
polymerase chain reaction (qRT-PCR). Differences between groups were tested for significance using Student’s t-test
(two-tailed). Then we analyzed the potential relationship between BC040587 expression and clinic pathological features
of BC patients. The correlation was analyzed by SPSS software.
Results: It showed that BC040587 expression was down regulated both in BC samples and in BC cell lines compared
with corresponding normal control. BC040587 expression was correlated with menopausal status (p = 0.040) and tumor
differentiation (p = 0.035). The Kaplan-Meier survival curves indicated that the overall survival (OS) was significantly poor
in low BC040587 expression BC patients (p = 0.023). Furthermore, expression of BC040587 was significantly associated
with worse prognosis and was shown to be an independent prognostic marker breast cancer (p = 0.032). Our studies
indicate that BC040587 may represent a new marker of prognosis in breast cancer.
Conclusion: Our studies indicate that BC040587 is significantly down-regulated in BC tissues and BC cell lines.
BC040587 may represent a new marker of prognosis in breast cancer.
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Accumulating evidence show that Long non-coding
RNAs (lncRNAs) play more and more important roles in
a wide range of biological processes. Aberrant lncRNAs
expression are involved in many cancers, such as glioma
[1,2], lung [3,4], breast [5-7], and liver cancers [8-10].
LncRNA are also found to function as new regulators in
cancer development [11]. Like protein-coding genes and
miRNAs, lncRNAs can function as oncogenes or tumor* Correspondence: wujiong1122@vip.sina.com
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unless otherwise stated.suppressors during cancer progression [12]. For example,
BANCR was found overexpressed in melanoma and re-
quired for full migratory capacity of melanoma cells by
upregulating CXCL11, an important gene involved in cell
migration [13]. lncRNA CRNDE which was highly
elevated in many solid tumors and in acute myeloid leuke-
mias (AML) can promote cell growth and suppress apop-
tosis, which supports a role for CRNDE as a mediator of
oncogenesis [14,15]. LncRNA MEG3 is found markedly
decreased in glioma tissues and ectopic expression of
lncRNA MEG3 inhibited cell proliferation and promoted
cell apoptosis via p53 activation in human glioma. Also,
the expression of lncRNA MEG3 was associated with
meningioma pathogenesis and progression [16,17].
Expression profiling of lncRNAs in human tumors
has identified their association with diagnosis, staging,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[12,18,19].
Many lncRNAs such as HOTAIR, which has been impli-
cated in several cancers, such as lung cancer [4,20], gastric
cancer [21], esophageal squamous cell carcinoma [22],
colorectal cancers [23], have already shown their potential
as novel independent biomarkers for early diagnosis and
prognosis prediction in cancer. Meanwhile, lncRNA DD3
is also found to be a very sensitive and specific biomarker
for the detection of prostate tumor cell [24,25]. Another
recently reported study have shown that lncRNA HOT-
TIP and HOXA13, which expression were associated with
metastasis and survival in HCC patients revealed their
possible role of predictive biomarker of HCC [26].
Also more and more lncRNA are found to be associated
with breast cancer outcomes. For example, expression of
CCAT2, a novel long non-coding RNA in breast cancer
was found to be related with clinical outcomes [5]. Jiang
and his group also identified 122 putative breast cancer-
associated long intergenic non-coding RNA loci by high
density SNP array analysis [6]. Recent studies show that
breast cancer patients with high HOTAIR expression
had lower risks of relapse and mortality than those with
low HOTAIR expression [27]. So seeking novel molecular
lncRNA biomarkers of breast cancers is very important
and helpful for its clinical diagnosis and management.
Previous studies identified 3q13.31 as a novel region of
cooperatively acting tumor suppressor genes. BC040587
was located in the region 3q13.31, and it was found to be
associated with poor survival of osteosarcoma patients
[28]. Few studies were carried out in the other tumor type.
The aim of this study was to examine the role of
BC040587 in breast cancer and to confirm whether the
expression of BC040587 was aberrant in breast cancer tis-
sues and cancer cell lines and whether it was associated
with poor prognosis in breast cancer.
Results
BC040587 show low expression in breast cancer tissues
In order to examine the expression profile of BC040587
in breast cancer, we first detected the expression of
BC040587 in 20 pairs of breast cancer tissues and it
normal tissues. GAPDH was used as an internal con-
trol. 2-ΔCt values were used to determine their relative
expression. As shown in Figure 1A, BC040587 showed
much lower expression in breast cancer tissues than in
normal tissues. The p value was 0.01 and much less
than 0.05. These data indicated that BC040587 might
serve as a tumor suppressor in breast cancer.
Expression profile of BC040587 in breast cancer cell lines
and normal MCF10A cells
The expression of BC040587 was further examined in 9
breast cancer cell lines compared with the normal breastcell MCF10A. As shown in Figure 1B, compared with
normal breast cancer cell line MCF10A, the breast can-
cer cells had much lower BC040587 expression. These
data further suggested that expression of BC040587 was
relatively low in breast cancer and BC040587 was a can-
didate tumor suppressor in breast carcinogenesis.Correlations between BC040587 expression and clinical
characteristics
To identify the clinical relevance of BC040587 expres-
sion in breast cancer, correlation between BC040587
expression and clinic pathological parameters such as
age, menopausal status, histological grade, tumor size,
lymph node status and TNM stage were examined
(Table 1). To assess the correlation of BC040587 expres-
sion with clinicopathologic data, the expression levels of
BC040587 in tumor tissues were categorized as low or
high in relation to the mean value. Of the 151 breast can-
cer patients, 76 cases were in BC040587 high group, and
the other 75 cases were in the BC040587 low group. Chi-
Square tests are used to determine the cutoff value of
BC040587 high and BC040587 low group for the study.
BC040587 expression in breast cancer was significantly
correlated with menopausal status (p = 0.04), tumor differ-
entiation (p = 0.035). Postmenopausal patients had a rela-
tively low BC040587 expression level. Moreover, patients
with lower BC040587 expression tended to have a higher
risk of poor grade of tumor differentiation. However,
BC040587 expression in breast cancer was not associated
with other parameters such as age (p = 0.675), tumor loca-
tion (p = 0.79), tumor size (p = 0.356), ER status (p =
0.828), PR status (p = 0.900), P53 staus (p = 0.217), Ki67
status (p = 0.844), lymph node status (p = 0.489) and TNM
stage (p = 0.964) (Table 1).Association between BC040587 expression and patient
survival
All patients were followed up for at least 5 years. Over-
all survival curves in low and high BC040587 expres-
sion groups were shown in Figure 2, and the overall
survival was significantly lower in patients with lower
BC040587 expression than those with high expression
(p = 0.012). The Disease free survival showed no signifi-
cance (Data not shown).
Univariate analysis (Log-rank test) of prognostic pa-
rameters for OS was performed. As shown in Table 2,
patients with low BC040587 were significantly associ-
ated with a poorer OS (p = 0.031), HR positive patients
were also associated with a good OS (p = 0.045). Multi-
variate analysis using Cox’s regression model was per-
formed as shown in Table 3. HR status (p = 0.050) was
shown to be border-line significant in multivariate ana-
lysis. And BC040587 expression (p = 0.032), and lymph
Figure 1 BC040587 show low expression in breast cancer tissues and breast cancer cell lines. A. Comparison of BC040587 expression levels
between 20 pairs of BC tumor tissues and ANCT normal tissues by qRT-PCR analysis. GAPDH was used as an internal control (p < 0.01). B. Comparison
of BC040587 expression levels between 9 BC cell lines and normal MCF10A cells by qRT-PCR analysis. GAPDH was used as an internal control.
Abbreviations represent that 231, MDA-MB-231; 231HM, lung highly metastasis MDA-MB-231; 436, MDA-MB-436; 468, MDA-MB-468.
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Discussion
Breast cancer is the most common female cancer and
among the most frequent causes of cancer mortality in
women worldwide. Also, cancer is a complex disease, in-
volving various changes in gene expression. As a newly
discovered class of non-coding genes, altered expression
of lncRNAs is frequently observed in human cancers, in-
cluding breast cancer [1]. The alterations in the expres-
sion, the primary structure, secondary structure as well
as their binding proteins are often associated with metas-
tasis, invasion and patient survival. It suggested that the
potential role of lncRNAs should be further investigated.
We present evidence here that BC040587 was down
regulated in the breast cancer tissues as well as breast
cancer cells and it low expression may contribute to the
patient poor survival.
BC040587 is located at chromosome 3q13.31 [2]. As
the 3q13.31 locus harbors frequent focal copy numberalterations (CNAs) and loss of heterozygosity in primary
osteosarcoma samples [3], it implies that BC040587 may
function as a potential tumor suppressor in osteosar-
coma samples [4,2]. However, little is known about the
role of BC040587 in breast cancer.
We show that expression of BC040587 was down regu-
lated in breast cancer tissues compared with the ANCT in
20 pairs of patients (p < 0.05). Furthermore, expression of
BC040587 was attenuated in most breast cancer cell lines
compared with the normal breast cancer cell line
MCF10A. These data suggest that BC040587 may also
function as a tumor suppressor in breast cancer. Then re-
lationship between BC040587 expression and clinicopath-
ological features in breast cancer patients was then
examined. It showed that expression of BC040587 was
relatively lower in the postmenopausal stage than in the
premenopausal stage (p = 0.040). It was supposed that the
expression of BC040587 might be effected by the endo-
crine system. There are no correlated reports. However,
expression of BC040587 had no significant association
with ER and PR status in our research. It needs further
Table 1 Relationship between BC040587 expression and
clinicopathological features in breast cancer patients
loc285194
Characteristics Low High n X2 p
Age(years) 0.175 0.675
<50 32 (47.8%) 35 (52.2%) 67
≥50 43 (51.2%) 41 (48.8%) 84
Menopausal status 4.199 0.040
Pre 28 (40.6%) 41 (59.4%) 69
Post 47 (57.3%) 35 (42.7%) 82
MT Family Hix 0.028 0.867
No 61 (48.8%) 64 (51.2%) 125
Yes 14 (48.3%) 15 (51.7%) 29
Tumor size (cm) 0.853 0.356
≦2 cm 22 (44%) 28 (56%) 50
>2 cm 52 (52%) 48 (48%) 100
Node status 0.479 0.489
Negative 36 (45%) 44 (55%) 80
Positive 33 (50.8%) 32 (49.2%) 65
ER status 0.047 0.828
Negative 26 (48.1%) 28 (51.9%) 54
Positive 47 (50%) 47 (50%) 94
PR status 0.016 0.900
Negative 28 (50%) 28 (50%) 56
Positive 46 (48.9%) 48 (51.1%) 94
HER-2 status 0.342 0.559
Negative 44 (51.8%) 41 (48.2%) 85
Positive 31 (47%) 35 (53%) 66
P53 status 1.525 0.217
Negative 25 (44.6%) 31 (55.4%) 56
Positive 31 (56.4%) 24 (43.6%) 55
Ki67 status 0.039 0.844
Negative 35 (50.7%) 34 (49.3%) 69
Positive 20 (48.8%) 21 (51.2%) 41
Differentiation 4.468 0.035
Well 34 (43%) 45 (57%) 79
Poor 35 (61.4%) 22 (38.6%) 57
TNM stage 0.002 0.964
III 53 (47.3%) 59 (52.7%) 112
III 15 (46.9%) 17 (53.1%) 32
Abbreviations: ER estrogen receptor, HER-2 human epidermal growth factor
receptor 2, PR progesterone receptor, MT Family Hix malignant tumor family
history. Symbol Bold Data mean p<0.05.
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of BC040587 was related to poor tumor differentiation
(p = 0.035). These data suggest that BC040587 mayfunction as a potential tumor suppressor and a predictive
biomarker in breast cancer.
The overall survival was significantly lower in patients
with lower BC040587 expression than those with high ex-
pression (p = 0.012) which was consistent with reports of
tumor-suppressive role of BC040587 in osteosarcoma. Uni-
variate analysis (Log-rank test) of prognostic parameters for
OS showed that patients with low BC040587 were signifi-
cantly associated with a poorer OS (p = 0.031). HR positive
patients were also significantly associated with a good OS
(p = 0.045). Multivariate analysis was examined to found
BC040587 expression (p = 0.032) was an independent prog-
nostic indicator for OS in addition with lymphatic metasta-
sis (p = 0.047) and HR status (p = 0.05) (Table 3).
As we known, lncRNAs impact cellular functions
through various mechanisms, such as interactions with
chromatin remodeling proteins [29,30], they are able to
regulate other non-coding RNAs, in particular micro-
RNAs. For example, loc285194 is a p53-regulated tumor
suppressor, which acts in part through repression of miR-
211 [31]. We speculated that BC040587 might regulated
by other powerful genes or it could regulate other genes
to play its special roles and function as a tumor suppressor
in breast cancer. However, little was known about the BC
040587 signaling pathway, it needs further investigation.Conclusion
BC040587 was significantly down-regulated in BC com-
pared with ANCT. Expression of BC040587 was low in the
postmenopausal patients with poor tumor differentiation
and poor survival. Our results suggest that attenuated ex-
pression of BC040587 may play an important role in BC
and it could be an independent prognostic biomarker in
breast cancer.Materials and methods
Patients’ samples
A total of 151 primary breast cancer samples of stage I
to III invasive ductal carcinoma cases and ANCT were
collected randomly at the Department of Breast Surgery
in Fudan University Shanghai Cancer Center (FDUSCC,
Shanghai, P.R. China). Each case was given a unique
identifier and linked to a database containing clinical-
pathological data. ANCT means the normal breast tis-
sue and it was diagnosed by the pathologists through
H.E. staining. The tumors were assessed according to
the WHO classification by two academic pathologists.
In addition, the pathological data including (ER, PR),
HER2, P53 and Ki67 status/expression were assessed
and diagnosed by the pathologists based on the ASCO
breast cancer guideline. Patient information and tumor
pathology are summarized. This study was approved by
the Ethical Committee of Fudan University Shanghai
Figure 2 Kaplan–Meier survival curves of patients with breast cancer based on BC040587 expression status. Patients in the lower
expression group had significantly poorer prognosis than those in low expression group (p < 0.05).
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formed consents were obtained from all the patients.Cell culture and regents
Fifteen breast cell lines were obtained from cell bank of
our lab. ZR-75-30, MCF-7, SKBR-3 and T47D cells
were grown using 1640 medium. MDA-MB231, MDA-
MB231HM cells were cultured using F15. MDA-MB436,
MDA-MB468, Hs578T cells were cultured with DMEM
medium. MCF10A were cultured with F12/DMEM 1:1Table 2 Univariate regression model of prognostic




Age(<50/> = 50) 1.008 0.350 2.908 0.988
Menopause(positive/negative) 1.908 0.598 6.093 0.275
Differentiation(good/bad) 2.441 0.816 7.303 0.111
MT Family Hix(positive/negative) 1.276 0.355 4.584 0.708
Tumorsize(≦/>2 cm) 1.374 0.430 4.388 0.592
Lymph node(positive/negative) 3.125 0.828 11.792 0.093
TNM( I + II/III) 0.672 0.145 3.122 0.612
HR status (positive/negative) 0.326 0.109 0.974 0.045
HER2 status (positive/negative) 1.358 0.650 2.837 0.416
BC040587 (high/low) 0.245 0.068 0.879 0.031
Abbreviations: CI confidence interval, HR status hormone receptor status,
HER-2 human epidermal growth factor receptor 2, HR hazard ratio, MT Family
Hix malignant tumor family history. Symbol Bold Data mean p<0.05.medium. All medium are with 10% FBS, 100 units/ml
penicillin, and 100 ug/ml streptomycin. The cells were
cultured at 37°C and 5% CO2.RNA extraction and Quantitative RT-PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen). After converting total RNA to cDNA in a reverse
transcription (RT) reaction, qPCR were used to quantitate
the mRNA expression levels. To detect BC040587 expres-
sion, we used the SYBR.
Green method with primers listed below: BC040587
exon 2 forward 5′ TAACAAGATTCACCTGCCAACC
3′ and BC040587 exon 2 reverse 5′ TGAGATCCAGAG
TGTGCTGAAA 3′. GAPDH was used as an internal
control. 2-delta Ct values were used to determine their rela-
tive expression.Table 3 Multivariate analysis of clinicopathological




Lymph node(positive/negative) 3.891 1.014 14.907 0.047
TNM(I + II/III) 0.152 0.021 1.103 0.063
HR status (positive/negative) 0.335 0.112 1.000 0.050
HER2 status (positive/negative) 1.663 0.581 4.763 0.343
BC040587 (high/low) 0.248 0.069 0.890 0.032
Abbreviations: CI confidence interval, HR status hormone receptor status,
HER-2 human epidermal growth factor receptor 2, HR hazard ratio. Symbol
Bold Data mean p≦0.05.
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Analyses were performed using SPSS software. Kaplan-
Meier survival analysis was also performed using SPSS.
Differences with p-values <0.05 are considered significant.
Univariate analysis were used in multivariate analysis on
the basis of Cox proportional hazards model. Two-sided
p-values were calculated and a probability level of 0.05
was chosen for statistical significance.
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